TCM
NKTR icon

Tang Capital Management’s Nektar Therapeutics NKTR Stock Holding History

Tang Capital Management’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-35,973
Closed -$2.91M – 69
2022
Q1 		$2.91M Buy
+35,973
New +$5.32M 0.58% 40

Other funds holding NKTR

DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MAM
Monaco Asset Management Monaco $542M AUM 54.4% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Tang Capital Management's NKTR Position: Q1 2024 in Review

Tang Capital Management sold out of Nektar Therapeutics (NKTR) in Q1 2024, closing a stake of 156,541 shares — an estimated $1.33M sold.

Tang Capital Management first reported a position in NKTR in Q2 2013 and held it in 11 quarters. The position peaked at $10.5M in Q2 2013. 124 funds tracked by Wall St. Rank hold NKTR as of Q1 2024.

  • Tang Capital Management reported no remaining Nektar Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Tang Capital Management sold 156,541 Nektar Therapeutics shares in Q1 2024, an estimated $1.33M.
  • Tang Capital Management first reported a position in Nektar Therapeutics in Q2 2013 and held it in 11 quarters.
  • Tang Capital Management's Nektar Therapeutics position peaked at $10.5M in Q2 2013.
  • 124 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q1 2024.

Based on Tang Capital Management's 13F filing for Q1 2024, filed 15 May 2024.